Across TCGA pan-cancer cohorts, ZFP69B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZFP69B data layer compared with 27 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ZFP69B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ZFP69B expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

BLCA, UCEC, and SKCM are the cancer types where ZFP69B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	II,III,IV	0.827	0.323	.022	13	view →
UCEC	DFS	Median	All	0.957	0.626	.022	10	view →
SKCM	DFS	Median	III,IV	1.000	0.242	.010	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ZFP69B tumor-vs-normal RNA expression · all ZFP69B data types